



Wolf-Dieter Janthur

Contact

Wolf-Dieter Janthur

Publications (4)

Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühl-Schill C, Früh M, Mauti L. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. *JTO Clin Res Rep* 2024; 5:100735.

Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörgler M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. *J Clin Oncol* 2021; 39:2872-2880.

Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitler M, Wannesson L, Jörgler M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. *Cancer Immunol Immunother* 2020

Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. *Cancer Immunol Immunother* 2020; 69:1605-1613.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch